Asia Pac Allergy.  2017 Jan;7(1):51-53. 10.5415/apallergy.2017.7.1.51.

Hypersensitivity to ticagrelor and low response to clopidogrel: a case report

• Dai J
• Lyu S
• Ge C

• KMID: 2396915
• DOI: http://doi.org/10.5415/apallergy.2017.7.1.51

Abstract

Ticagrelor is widely used to treat acute coronary syndrome. Hypersensitivity reaction of ticagrelor is rarely recognized. A low response to clopidogrel, which occurs in up to 23% of patients, is an independent risk factor for stent thrombosis. Management of patients with a low response to clopidogrel and ticagrelor hypersensitivity who are undergoing antithrombotic therapy remains to be a challenge. Herein, we report a patient with low response to clopidogrel and ticagrelor hypersensitivity, who was successfully managed using aspirin and warfarin.

Keyword

Antiplatelet therapy; Hypersensitivity; Low response; Ticagrelor; Clopidogrel; Warfarin

MeSH Terms

Acute Coronary Syndrome
Aspirin
Humans
Hypersensitivity*
Risk Factors
Stents
Thrombosis
Warfarin
Aspirin
Warfarin

Reference

1. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006; 27:2420–2425.

2. Jacobson KA, Boeynaems JM. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov Today. 2010; 15:570–578.

3. Quinn KL, Connelly KA. First report of hypersensitivity to ticagrelor. Can J Cardiol. 2014; 30:957.e3–957.e4.

4. Birkeland K, Parra D, Rosenstein R. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med. 2010; 1:197–219.

5. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010; 38:1514–1521.

6. Baker WL, White CM. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Am J Cardiovasc Drugs. 2009; 9:213–229.

7. Chin N, Rangamuwa K, Mariasoosai R, Carnes J, Thien F. Oral antiplatelet agent hypersensitivity and cross-reactivity managed by successful desensitisation. Asia Pac Allergy. 2015; 5:51–54.

8. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:2 Suppl. e152S–e184S.

9. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003; 41:1633–1652.